| 1. |
Wijsenbeek M, Suzuki A, Maher TM, et al. Interstitial lung diseases[J]. Lancet, 2022, 400(10354): 769-786.
|
| 2. |
Podolanczuk AJ, Hunninghake GM, Wilson KC, et al. Approach to the Evaluation and Management of Interstitial Lung Abnormalities: an Official American Thoracic Society Clinical Statement[J]. Am J Respir Crit Care Med, 2025, 211(7): 1132-1155.
|
| 3. |
van der Sar IG, Jones S, Clarke DL, et al. Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey[J]. Front Med (Lausanne), 2021, 8: 711194.
|
| 4. |
Hoyer N, Prior TS, Bendstrup E, et al. Risk Factors for Diagnostic Delay in Idiopathic Pulmonary Fibrosis[J]. Respir Res, 2019, 20: 103.
|
| 5. |
Cosgrove GP, Bianchi P, Danese S, et al. Barriers to Timely Diagnosis of Interstitial Lung Disease in the Real World: the INTENSITY Survey[J]. BMC Pulm Med, 2018, 18: 9.
|
| 6. |
Rodrigues I, Estêv?o Gomes R, Coutinho LM, et al. Diagnostic Yield and Safety of Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in Interstitial Lung Diseases: a Systematic Review and Meta-Analysis[J]. Eur Respir Rev, 2022, 31: 210280.
|
| 7. |
Johannson KA, Chaudhuri N, Adegunsoye A, et al. Treatment of Fibrotic Interstitial Lung Disease: Current Approaches and Future Directions[J]. Lancet, 2021, 398(10358): 1450-1460.
|
| 8. |
戴曦, 鄢潔, 李玉英. 健康中國行動賦能慢性呼吸系統疾病全程管理[J]. 西南醫科大學學報, 2025, 48: 456-459.
|
| 9. |
史媛婷, 李菲. 國內外慢病管理平臺建設比較[J]. 中國科技信息, 2024, 128-130.
|
| 10. |
宋艷. 電話隨訪在慢病隨訪中的應用[J]. 中國保健營養, 2021, 31: 271.
|
| 11. |
呂旭東, 田琪, 蔡海領, et al. 臨床科研數據庫平臺關鍵技術研究與實現[J]. 中國數字醫學, 2021, 16: 23-29.
|
| 12. |
健康中國行動—慢性呼吸系統疾病防治行動實施方案 (2024—2030 年)[J]. 養生大世界, 2024: 7-10.
|
| 13. |
Spagnolo P, Ryerson CJ, Putman R, et al. Early Diagnosis of Fibrotic Interstitial Lung Disease: Challenges and Opportunities[J]. Lancet Respir Med, 2021, 9(9): 1065-1076.
|
